Skip to main content

Melphalan flufenamide Disease Interactions

There are 3 disease interactions with melphalan flufenamide.

Major

Antineoplastics (applies to melphalan flufenamide) infections

Major Potential Hazard, Moderate plausibility. Applicable conditions: Infection - Bacterial/Fungal/Protozoal/Viral

Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression. The use of these drugs may be contraindicated in patients with known infectious diseases. All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy. Close clinical monitoring of hematopoietic function is recommended.

References

  1. (2002) "Product Information. Methotrexate (methotrexate)." Lederle Laboratories
  2. (2001) "Product Information. Platinol (cisplatin)." Bristol-Myers Squibb
  3. (2001) "Product Information. Vepesid (etoposide)." Bristol-Myers Squibb
  4. (2001) "Product Information. Novantrone (mitoxantrone)." Immunex Corporation
  5. (2001) "Product Information. Mutamycin (mitomycin)." Bristol-Myers Squibb
  6. (2001) "Product Information. Ifex (ifosfamide)." Bristol-Myers Squibb
  7. (2001) "Product Information. Thiotepa (thiotepa)." Hikma USA (formerly West-Ward Pharmaceutical Corporation)
  8. (2001) "Product Information. Fludara (fludarabine)." Berlex Laboratories
  9. (2001) "Product Information. Idamycin (idarubicin)." Pharmacia and Upjohn
  10. (2001) "Product Information. Matulane (procarbazine)." Roche Laboratories
  11. (2001) "Product Information. DTIC-Dome (dacarbazine)." Bayer
  12. (2001) "Product Information. Adriamycin PFS (doxorubicin)." Pharmacia and Upjohn
  13. (2001) "Product Information. Leustatin (cladribine)." Ortho Biotech Inc
  14. (2001) "Product Information. Gemzar (gemcitabine)." Lilly, Eli and Company
  15. (2001) "Product Information. Hycamtin (topotecan)." SmithKline Beecham
  16. (2001) "Product Information. Taxotere (docetaxel)." Rhone Poulenc Rorer
  17. (2001) "Product Information. Taxol (paclitaxel)." Bristol-Myers Squibb
  18. (2001) "Product Information. Nipent (pentostatin)." Hospira Inc
  19. (2001) "Product Information. Tabloid (thioguanine)." Prasco Laboratories
  20. (2001) "Product Information. Xeloda (capecitabine)." Roche Laboratories
  21. (2022) "Product Information. Alkeran (melphalan)." Glaxo Wellcome
  22. (2001) "Product Information. Purinethol (mercaptopurine)." Glaxo Wellcome
  23. "Product Information. Leukeran Tablets (chlorambucil)." Glaxo Welcome, Research Triangle Pk, NC.
  24. (2001) "Product Information. Doxil (doxorubicin liposomal)." Sequus Pharmaceuticals Inc
  25. (2001) "Product Information. Cytosar-U (cytarabine)." Pharmacia and Upjohn
  26. (2001) "Product Information. Uracil Mustard (uracil mustard)." Roberts Pharmaceutical Corporation
  27. (2010) "Product Information. Jevtana (cabazitaxel)." sanofi-aventis
  28. (2010) "Product Information. Halaven (eribulin)." Eisai Inc
  29. (2021) "Product Information. Pepaxto (melphalan flufenamide)." Oncopeptides Inc.
View all 29 references
Moderate

Melphalan flufenamide (applies to melphalan flufenamide) bone marrow suppression

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Bone Marrow Depression/Low Blood Counts

Bone marrow suppression is the most significant toxicity associated with melphalan flufenamide in most patients. It is recommended to perform the following tests at the start of therapy and prior to each subsequent dose of melphalan flufenamide: platelet count, hemoglobin, white blood cell count, and differential. Thrombocytopenia and/or neutropenia are indications to withhold further therapy until the blood counts have sufficiently recovered. Monitor blood counts frequently to determine optimal dosage and to avoid toxicity. Consider prophylactic therapy such as leukocyte growth factor as clinically appropriate. Dose adjustment on the basis of blood counts at the nadir and day of treatment should be considered.

References

  1. (2021) "Product Information. Pepaxto (melphalan flufenamide)." Oncopeptides Inc.
Moderate

Melphalan flufenamide (applies to melphalan flufenamide) renal dysfunction

Moderate Potential Hazard, Moderate plausibility.

No dose adjustment of melphalan flufenamide is recommended in patients with creatinine clearance (CrCl) 45 to 89 mL/min. Care should be exercised when using this agent in patients with CrCl 15 to 44 mL/min as the safety and efficacy has not been studied in these patients.

References

  1. (2021) "Product Information. Pepaxto (melphalan flufenamide)." Oncopeptides Inc.

Melphalan flufenamide drug interactions

There are 253 drug interactions with melphalan flufenamide.

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer